Moleculin reports interim results from MIRACLE trial in r/r AML patients

Data ReadoutAnnAraCNeutral

AI Analysis

Summary

Moleculin Biotech reported preliminary blinded interim data from Part A of its Phase II/III MIRACLE trial evaluating AnnAraC in adult patients with relapsed/refractory acute myeloid leukemia. No specific efficacy or safety details were disclosed in this announcement.

Clinical Trial Data

Phase

Phase 2/3

Outcome Details

Preliminary blinded interim data from Part A reported

Importance:5/10

Sentiment:

0.00

AMLrelapsed/refractoryinterim datapivotal trial

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 3, 2026 8:51 AM

Read Original